Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab as Neoadjuvant Therapy for Oral Cavity Cancer
NCT03021993Phase 2Completed
- Sponsor
- Medical University of South Carolina
- Start
- May 2017
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in oral cavity squamous cell carcinoma (OCSCC), sponsored by Medical University of South Carolina. Primary endpoint: Objective Response Rate Using Pathological Response at Day 50. Started May 2017; status: completed.
02
Drugs
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)
Beyond the preview
Go deeper on NCT03021993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03021993.